Paul Sohmer - BG Medicine President CEO, Director
| BGMDDelisted Stock | USD 0.0002 0.00 0.00% |
CEO
Dr. Paul R. Sohmer, M.D., is President, Chief Executive Officer, Director of BG Medicine, Inc., since May 8, 2013. Dr. Sohmer served as President and Chief Executive Officer of ViracorIBT Laboratories, Inc., a diagnostic and research laboratory specializing in allergy, immunology, and infectious disease testing from January 2011 to September 2012. Prior to joining ViracorIBT Laboratories, from February 2009 to January 2011, Dr. Sohmer served as Chief Executive Officer of Orthocon, Inc., a company that develops, manufactures, markets, and sells implantable products designed to stop bone bleeding. From 2007 to 2009, Dr. Sohmer served on the RadPharm, Inc. Board of Directors, and from 2008 to 2009, he served as Chairman of the Board of Directors of Molecular Biometrics, Inc. Dr. Sohmer served as Interim CEO of Cylex, Inc. from January through March of 2008 and CEO of Pathway Diagnostics from May to September of 2008. From June 2000 to December 2006, Dr. Sohmer served as Chairman, President and Chief Executive Officer of TriPath Imaging, Inc. . From 1997 to 2000, Dr. Sohmer served as President and Chief Executive Officer of Neuromedical Systems, Inc. . From 1992 to 1996, Dr. Sohmer served as President and Chief Executive Officer of Genetrix, Inc., a genetic testing lab. From 1991 to 1992, Dr. Sohmer served as Vice President of Professional Services for Nichols Institute. From 1985 to 1991, Dr. Sohmer served as President and Chief Executive Officer of Pathology Institute, Inc., where he led the first commercial introduction of polymerase chain reaction for diagnosis of HIV and founded the Chiron Reference Laboratory since 2013.
| Age | 74 |
| Tenure | 11 years |
| Phone | 781 890 1199 |
| Web | https://www.bg-medicine.com |
BG Medicine Management Efficiency
The company has return on total asset (ROA) of (0.7595) % which means that it has lost $0.7595 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (9.0264) %, meaning that it created substantial loss on money invested by shareholders. BG Medicine's management efficiency ratios could be used to measure how well BG Medicine manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | CEO Age | ||
| Harrison Gross | Innovative Eyewear | 31 | |
Management Performance
| Return On Equity | -9.03 | ||||
| Return On Asset | -0.76 |
BG Medicine Management Team
Elected by the shareholders, the BG Medicine's board of directors comprises two types of representatives: BG Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BGMD. The board's role is to monitor BG Medicine's management team and ensure that shareholders' interests are well served. BG Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BG Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Aram Adourian, Chief Scientific Officer and Sr. VP | ||
| Stephen Hall, CFO, Principal Accounting Officer, Executive VP and Treasurer | ||
| Paul Sohmer, President CEO, Director |
BGMD Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is BG Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -9.03 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (2.86) % | ||||
| Current Valuation | 545.97 K | ||||
| Shares Outstanding | 11.37 M | ||||
| Number Of Shares Shorted | 630.05 K | ||||
| Price To Earning | (0.06) X | ||||
| Price To Sales | 0.35 X | ||||
| Revenue | 1.57 M | ||||
| Gross Profit | 1.06 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in BGMD Pink Sheet
If you are still planning to invest in BG Medicine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BG Medicine's history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |